search

Active clinical trials for "Myositis"

Results 71-80 of 140

Blood-flow Restricted Exercise in Inclusion Body Myositis

Sporadic Inclusion Body Myositis

This study evaluates the effects of a low-intensity blood-flow restricted exerciser protocol on patient reported physical function, in patients with sporadic inclusion body myositis. The study is designed as a parallel group randomized controlled trial with a treatment group and a control group.

Completed9 enrollment criteria

Anakinra in Myositis

PolymyositisDermatomyositis1 more

To investigate the effect of the interleukin-1 (IL-1) blocking agent, anakinra, in patients with treatment-resistant inflammatory myopathies. Patients and methods: Fifteen patients with refractory polymyositis (PM), dermatomyositis (DM), or inclusion body myositis (IBM) were treated with 100 mg anakinra subcutaneously per day during 12 months. Outcome measures included myositis disease activity score with improvement defined according to The International Myositis Assessment and Clinical Studies Group (IMACS) and for muscle performance the functional index of myositis (FI). In addition repeat muscle biopsies were performed

Completed4 enrollment criteria

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis

This study will assess the efficacy, safety and tolerability of BYM338 in patients with sporadic Inclusion Body Myositis

Completed5 enrollment criteria

Arimoclomol in Sporadic Inclusion Body Myositis

Inclusion Body Myositis

Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age. This study will assess the safety and tolerability of Arimoclomol in IBM as compared to placebo over 4 months of treatment.

Completed15 enrollment criteria

JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM

Idiopathic Inflammatory Myopathies

This study aims to investigate the clinical efficacy of baricitinib in patients with adult idiopathic inflammatory myositis (IIM). Half of the patients enrolled onto the study will receive 24 weeks of baricitinib from the baseline visit with a 12 week follow-up period. The other half of patients will receive 24 weeks of barcitinib treatment after an initial 12-week delay with a 4 week follow up period for safety.

Completed47 enrollment criteria

Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis

Inclusion Body MyositisSporadic Inclusion Body Myositis

This is a pilot study (phase 1 clinical trial) to evaluate the safety and tolerability of phenylbutyrate in IBM. In this open label study, 10 patients with sporadic inclusion body myositis will be treated with phenylbutyrate (3 gm twice daily) for 3 months. There will be a run-in period, during which certain biomarkers will be measured at baseline and at the end of the run-in period in addition to final measurement at the end of the treatment period.

Completed15 enrollment criteria

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With...

Sporadic Inclusion Body Myositis

This extension study will provide data to further evaluate the efficacy, safety, and tolerability of three doses of BYM338 and to assess the long-term effects of BYM338 in patients with sporadic inclusion body myositis. The extension study was planned to consist of a Screening epoch (to assess patient eligibility), followed by a Treatment Period 1 epoch (double-blind and placebo-controlled), and a Treatment Period 2 epoch (open-label). A Post-treatment Follow-up (FUP) epoch was also planned for patients who discontinued prematurely. Patients who complete the core study and qualify for this extension study entered Treatment Period 1 and continued on the study drug to which they were randomized in the core study (either to one of the three bimagrumab doses (1 mg/kg, 3 mg/kg, and 10mg/kg) or placebo) during Treatment Period 1. Thus, Treatment Period 1 was double-blind and placebo-controlled. Participants were to continue in Treatment Period 1 until the dose with the best benefit-risk profile was determined from the core study data and selected (duration of Treatment Period 1 was estimated to be between 6 and 8 months). Once the dose with the best benefit-risk profile was selected, all participants (including those who were receiving placebo) were planned to enter Treatment Period 2 and switch to open-label treatment with bimagrumab at the selected dose. The core study has been completed but since the core study did not meet the primary end point (no bimagrumab dose was identified based on the core study efficacy results) the extension study was terminated as per protocol/sponsor's decision; therefore, no patients had entered Treatment Period 2. Instead, all patients were to return for the End of Treatment Period 1 (EOT1) visit at their next scheduled visit. As per protocol, all patients who discontinued study medication during Treatment Period 1 for any reason, including due to the study having been stopped as per protocol/sponsor's decision, were to have entered and complete the 6-month FUP after their EOT1 visit. Due to the nature of the design of the core and extension studies and termination of study medication in the extension study, the treatment duration for individual patients varied considerably. Consequently, the number of patients contributing data to the efficacy analyses at Week 104 and later timepoints was decreased.

Completed11 enrollment criteria

Kinesio Taping Effects Applied With Different Directions and Tensions

MYOSITIS

The Kinesio Taping (KT ) method was developed more than thirty years ago in order to cause sensory effects through the epidermis and dermis, generating a variety of physiological effects in other systems. Clinical effects are well known levels in muscle, neurological system, injuries, inflammation, edema, among other physiological effects are thus largely in the theoretical framework. Objectives: The aim of this study is to evaluate the Electromyographic (EMG), Electroencephalographic (EEG), muscle temperature and flexibility effects with the Rectus Femoral muscle KT application. Methods: This is a pilot study with six subjects in which they were divided into two groups, A and B. Group A received the application of KT from muscle Origin to Insertion and group B Insertion to Origin, with both groups taped the non-dominant limb and the dominant limb was used as control group. The first application was conducted at 0% and the second with 75 to 100% tension. Evaluations were performed before the first application, immediately and 24 hours later. After this last evaluation, was withdrawn taping, evaluated without taping, reapplied 75 to 100 % of rated voltage and in sequence. The sixth last review was conducted 24 hours after this last application. Before every application a specific vibration was performed on the patellar tendon in order to trigger a neurophysiological imbalance rectus femoral.

Completed9 enrollment criteria

Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD

Interstitial Lung DiseaseScleroderma2 more

Interstitial lung disease (ILD) is characterised by inflammation and scarring of the lung and is the leading cause of death in patients with systemic sclerosis, and contributes significantly to morbidity and mortality in many other connective tissue diseases (CTDs) such as polymyositis/dermatomyositis and mixed connective tissue disease. When ILD is extensive and/or progressive, immunosuppressive medication is often required to stabilize lung disease and alleviate symptoms. Current standard care for CTD associated ILD is extrapolated from studies performed in individuals with systemic sclerosis and comprises low dose corticosteroids and intravenous cyclophosphamide followed by oral azathioprine. In some individuals even this intensive immunosuppression is insufficient to prevent deterioration, and in a significant minority of affected individuals this results in respiratory failure and death. Rituximab has recently been reported as an effective 'rescue therapy' for stabilizing and even improving ILD in this patient group. Based on observations gained from this experience, the investigators believe that rituximab is a potential important alternative to current best therapy for this patient group. This study has therefore been initiated to evaluate the efficacy of rituximab (compared with standard therapy) in patients with progressive CTD related ILD.

Completed24 enrollment criteria

Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With...

Inclusion Body Myositis

Inclusion body myositis (IBM) is the most common late onset acquired muscle disease. Patients develop progressive weakness that may result in the need for assistive devices including a wheelchair. IBM may be due to abnormal immune activation, due in part to overproduction of tumor necrosis factor (TNF)-alpha. Etanercept blocks the activity of TNF-alpha, thereby blunting immune overactivation. Previous unblinded studies and case reports suggest that etanercept may improve strength or slow the progressive weakness in IBM. We are conducting a double-blind, randomized, placebo-controlled study to test if Etanercept is beneficial in slowing the progressive weakness in patients with IBM.

Completed24 enrollment criteria
1...789...14

Need Help? Contact our team!


We'll reach out to this number within 24 hrs